US 11,053,304 B1
Anti-SARS-Cov-2 antibodies derived from 6nb6
Jacob Glanville, San Francisco, CA (US); Shahrad Daraeikia, San Francisco, CA (US); I-Chieh Wang, San Bruno, CA (US); Sindy Andrea Liao-Chan, San Jose, CA (US); Jean-Philippe Bürckert, Belmont, CA (US); and Sawsan Youssef, Menlo Park, CA (US)
Assigned to Centivax, Inc., South San Francisco, CA (US)
Filed by Centivax, Inc., South San Francisco, CA (US)
Filed on May 14, 2020, as Appl. No. 15/931,648.
Claims priority of provisional application 63/014,511, filed on Apr. 23, 2020.
Claims priority of provisional application 62/993,630, filed on Mar. 23, 2020.
Int. Cl. C07K 16/10 (2006.01); A61K 39/42 (2006.01); G01N 33/569 (2006.01); A61P 31/14 (2006.01); A61K 39/00 (2006.01)
CPC C07K 16/10 (2013.01) [A61P 31/14 (2018.01); G01N 33/56983 (2013.01); A61K 2039/505 (2013.01); C07K 2317/622 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01); G01N 2333/165 (2013.01)] 21 Claims
 
1. An antibody or an antigen-binding fragment that selectively binds to a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), that comprises a variable heavy chain (VH) complementarity determining region 1 (CDR1) having an amino acid sequence of SEQ ID NO: 136; a VH CDR2 having an amino acid sequence of SEQ ID NO: 190; a VH CDR3 having an amino acid sequence of SEQ ID NO: 223; a variable light chain (VL) CDR1 having an amino acid sequence of SEQ ID NO: 8; a VL CDR2 having an amino acid sequence of SEQ ID NO: 38; and a VL CDR3 having an amino acid sequence of SEQ ID NO: 120.